124I-FIAU Imaging in EBV and KSHV Associated Cancers

Inclusion Criteria:

Age 18 years or older.

EBV-positive or KSHV-associated malignancy, including but not limited to:

EBV+ Hodgkin lymphoma
EBV+ non-Hodgkin lymphoma or lymphoproliferative disease
Primary effusion lymphoma
Kaposi's sarcoma
EBV+ gastric cancer
EBV+ nasopharyngeal cancer
Measurable disease (at least one lesion measuring > 2 cm in longest axis).
ECOG performance status of 0, 1, or 2.
Patients must be able to lie flat for at least 60 minutes and fit on PET-CT scanner.

For post-therapy imaging with FIAU-PET, treatment with standard or investigational agents that can potentially activate herpesvirus TK, including but not limited to the following. Concurrent radiation therapy is permissible:

Platinum compounds (for example, cisplatin, carboplatin)
Anthracyclines (for example, doxorubicin or pegylated doxorubicin)
Tubulin disrupting agents (for example, vincristine, vinblastine)
Rituximab
Gemcitabine
Cytarabine
Histone deacetylase inhibitors
Bortezomib NOTE: Patients who would not receive bortezomib as part of their usual care may receive a one-time dose of bortezomib for the purpose of imaging with 124I-FIAU and FIAU-PET-CT.
AST and ALT < 3 X upper limit of normal, unless attributed to tumor, obtained within 2 weeks prior to registration.
Serum creatinine < 2.0 mg/dL, within 2 weeks prior to registration.

In patients who will receive bortezomib for imaging purposes only:

Total bilirubin < 1.5 X upper limit of normal, obtained within 2 weeks prior to registration.
Platelet count > 70,000 / mm3 obtained within 2 weeks prior to registration.
No pre-existing peripheral neuropathy greater than grade 1.

Exclusion Criteria:

End-stage liver disease unrelated to tumor.
Known active or chronic hepatitis B or hepatitis C infection.
History of iodine hypersensitivity.
Chronic renal insufficiency requiring dialysis.
Women who are pregnant or breast feeding.
Foreseen inability to comply with study requirements.